

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

WEH205

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/868887

INTERNATIONAL APPLICATION NO.

PCT/DE99/04102

INTERNATIONAL FILING DATE

17 DECEMBER 1999

PRIORITY DATE CLAIMED

21 DECEMBER 1998

TITLE OF INVENTION

CARDIO VASCULAR PROSTHESES WITH A STABLE ENDOTHELIAL SURFACE

APPLICANT(S) FOR DO/EO/US

MANRICO PAULITSCHKE, AXEL RADEMACHER, MICHAEL SITTINGER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☒ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

WETH 205

a. ☒ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-0224. A duplicate copy of this sheet is enclosed.

☒ Fees are to be charged to a credit card form PTO-2038  
is enclosed

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Horst M. Kasper  
13 Forest Drive  
Warren, N.J 07059

SIGNATURE: 

NAME  
Horst M. Kasper

28,559

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Manrico Paulitschke et al.

Serial No:

Art Unit:

Filing Date:

Title: CARDIOVASCULAR PROSTHESES WITH A STABLE  
ENDOTHELIAL CELL SURFACE

Examiner:

Priority Application: Germany, No.: 198 60 286.3

Priority Filing Date: 21 December 1998

PCT Application no: PCT/DE99/04102

PCT Application filing date: 17 December 1999

June 19, 2001

Attorney's Docket No.: WEH205

**PRELIMINARY AMENDMENT**

Hon. Commissioner of Patents and Trademarks

**Box PCT**

Washington, D.C. 20231

SIR:

This is a preliminary amendment to provide certain corrections in the above captioned patent application. The applicant petitions that, if required, the time for response be extended and the corresponding fee be charged. The Commissioner is hereby authorized to charge any additional fees which may be required to Acct. No. 11-0224. The Applicant further

respectfully requests that this response be accepted as a bona fide effort to meet any potential response requirements outstanding and due in the above captioned matter.

Please amend the application as follows:

**IN THE CLAIMS:**

### **CLEAN VERSION OF THE AMENDED CLAIMS:**

3. Cardiovascular prostheses according to claim 1, characterized in that the mathematical value of the increasing shear forces can be selected variably and time-independently.
4. Cardiovascular prostheses according to claim 1, characterized in that the mathematical value and the final value of the shear forces can be selected freely and time-variably by means of a program control according to the physiological conditions of the implantation location.
5. Cardiovascular prostheses according to claim 1, characterized in that the mathematical value of the occurring shear forces can be adjusted by varying the pumping capacity, as well as by varying the size of the cross-section of the pumping tubes used or of any other connecting elements outside of the chamber, as well as by the geometrical form and configuration of the very chamber.

6. Cardiovascular prostheses according to claim 1, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of adapters (3, 3'), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion circuit (5') for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connections to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.

7. Cardiovascular prostheses according to claim 1, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of an adapter (3), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion

circuit (5') uniting inside of the chamber (2) with the inner perfusion circuit (5) after having streamed the prosthesis (1) for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connectors to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoir.

8. Cardiovascular prostheses according to claim 6, characterized in that the outer perfusion circuit (5') can be operated in co-current or in counter-current to the inner perfusion circuit (5), but also statically.

9. Cardiovascular prostheses according to claim 6, characterized in that the perfusion circuits lead from one medium reservoir (6) into another medium reservoir (6'), in which the medium is collected which has already streamed through the prosthesis.

10. Cardiovascular prostheses according to claim 6, characterized in that the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6').

11. Cardiovascular prostheses according to claim 6, characterized in that the prosthesis is present in the very medium reservoir, and that the inner and the outer perfusion circuits are thereby connected with each another.

12. Cardiovascular prostheses according to claim 6, characterized in that the medium reservoirs are comprised of expandable blood bags of the materials PVC or EVAM.

13. Cardiovascular prostheses according to claim 6, characterized in that the realization of the adapters (3, 3') for fixing the prosthesis (1) can be realized as an olive, cones with clamping means or as an expansion member.



14. Cardiovascular prostheses according to claim 6, characterized in that the length of the prosthesis to be clamped can be varied by constructionally providing at least one closing part with the adapter (3 or 3') of chamber (2).

15. Cardiovascular prostheses according to claim 6, characterized in that the chamber (2) is manufactured from a transparent material.

16. Cardiovascular prostheses according to claim 1, characterized in that the prosthesis is used as a vascular prosthesis, a heart valve prosthesis or a stent.

17. Method for covering cardiovascular prostheses with endothelial cells according to claim 1, characterized in that after an initial sub-confluent seeding of the prosthesis surface on the blood contact side, the formation of a confluent monolayer ensues by the cells growing under permanent influence of defined pulsatile shear forces increasing up to physiological values by means of streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis in an inner perfusion circuit, and a

moistening of the outer prosthesis wall in an outer perfusion circuit or in a permeable medium reservoir.

19. The method according to claim 17, characterized in that in an inner perfusion circuit (5) for streaming through the inner prosthesis space along the main axis of the prosthesis inside of the chamber (2), the prosthesis (1) is fixed by means of adapters (3, 3'), and hence as such constitutes the inner perfusion circuit (5), and that an outer perfusion circuit (5') exists for outwardly streaming the prosthesis (1) in the same chamber (2) which, towards the outside, comprises for the two circuits (5, 5') connectors to a pumping device (7) and the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.

20. The method according to claim 17, characterized in that

- a) the outer perfusion circuit (5') can be operated in co-current or counter-current to the inner perfusion circuit (5), but also statically,
- b) the two perfusion circuits (5, 5') do not work as a closed system but lead from one medium reservoir (6) into another medium reservoir (6'), in

which the medium is collected which has already streamed through the prosthesis,

c) the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6'), and

d) the two perfusion circuits (5, 5') unite inside the chamber (2) after having streamed the prosthesis (1), but leave the chamber (2) in separate perfusion circuits (5, 5').

21. The method according to claim 17, characterized in that the prosthesis is present in the very medium reservoir and that the inner and the outer perfusion circuits are thereby connected with each another.

**MARKED-UP VERSION OF THE AMENDED CLAIMS:**

3. (amended) Cardiovascular prostheses according to [claims 1 and 2] claim 1, characterized in that the mathematical value of the increasing shear forces can be selected variably and time-independently.

4. (amended) Cardiovascular prostheses according to [claims 1 through 3] claim 1, characterized in that the mathematical value and the final value of the shear forces can be selected freely and time-variably by means of a program control according to the physiological conditions of the implantation location.

5. (amended) Cardiovascular prostheses according to [claims 1 through 4] claim 1, characterized in that the mathematical value of the occurring shear forces can be adjusted by varying the pumping capacity, as well as by varying the size of the cross-section of the pumping tubes used or of any other connecting elements outside of the chamber, as well as by the geometrical form and configuration of the very chamber.

6. (amended) Cardiovascular prostheses according to [claims 1 through 5] claim 1, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of adapters (3, 3'), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion circuit (5') for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connections to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.

7. (amended) Cardiovascular prostheses according to [claims 1 through 6] claim 1, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of an

adapter (3), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion circuit (5') uniting inside of the chamber (2) with the inner perfusion circuit (5) after having streamed the prosthesis (1) for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connectors to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoir.

8. (amended) Cardiovascular prostheses according to [claims 6 and 7] claim 6, characterized in that the outer perfusion circuit (5') can be operated in co-current or in counter-current to the inner perfusion circuit (5), but also statically.

9. (amended) Cardiovascular prostheses according to [claims 6 through 8] claim 6, characterized in that the perfusion circuits lead from one medium reservoir (6) into another medium reservoir (6'), in which the medium is collected which has already streamed through the prosthesis.

10. (amended) Cardiovascular prostheses according to [claims 6 through 8] claim 6, characterized in that the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6').

11. (amended) Cardiovascular prostheses according to [claims 6 through 8] claim 6, characterized in that the prosthesis is present in the very medium reservoir, and that the inner and the outer perfusion circuits are thereby connected with each another.

12. (amended) Cardiovascular prostheses according to [claims 6 through 11] claim 6, characterized in that the medium reservoirs are comprised of expandable blood bags of the materials PVC or EVAM.

13. (amended) Cardiovascular prostheses according to [claims 6 and 7] claim 6, characterized in that the realization of the adapters (3, 3') for fixing the prosthesis (1) can be realized as an olive, cones with clamping means or as an expansion member.

14. (amended) Cardiovascular prostheses according to [claims 6, 7 and 13] claim 6, characterized in that the length of the prosthesis to be clamped can be varied by constructionally providing at least one closing part with the adapter (3 or 3') of chamber (2).

15. (amended) Cardiovascular prostheses according to [claims 6 and 7] claim 6, characterized in that the chamber (2) is manufactured from a transparent material.

16. (amended) Cardiovascular prostheses according to [claims 1 through 15] claim 1, characterized in that the prosthesis is used as a vascular prosthesis, a heart valve prosthesis or a stent.

17. (amended) Method for covering cardiovascular prostheses with endothelial cells according to [claims 1 through 16] claim 1, characterized in that after an initial sub-confluent seeding of the prosthesis surface on the blood contact side, the formation of a confluent monolayer ensues by the cells growing under permanent influence of defined pulsatile shear forces



increasing up to physiological values by means of streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis in an inner perfusion circuit, and a moistening of the outer prosthesis wall in an outer perfusion circuit or in a permeable medium reservoir.

19. (amended) The method according to [claims 17 and 18] claim 17, characterized in that in an inner perfusion circuit (5) for streaming through the inner prosthesis space along the main axis of the prosthesis inside of the chamber (2), the prosthesis (1) is fixed by means of adapters (3, 3'), and hence as such constitutes the inner perfusion circuit (5), and that an outer perfusion circuit (5') exists for outwardly streaming the prosthesis (1) in the same chamber (2) which, towards the outside, comprises for the two circuits (5, 5') connectors to a pumping device (7) and the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.

20. (amended) The method according to [claims 17 through 19] claim 17, characterized in that

- a) the outer perfusion circuit (5') can be operated in co-current or counter-current to the inner perfusion circuit (5), but also statically,
- b) the two perfusion circuits (5, 5') do not work as a closed system but lead from one medium reservoir (6) into another medium reservoir (6'), in which the medium is collected which has already streamed through the prosthesis,
- c) the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6'), and
- d) the two perfusion circuits (5, 5') unite inside the chamber (2) after having streamed the prosthesis (1), but leave the chamber (2) in separate perfusion circuits (5, 5').

21. (amended) The method according to [claims 17 through 20] claim 17, characterized in that the prosthesis is present in the very medium reservoir and that the inner and the outer perfusion circuits are thereby connected with each another.

### ***REMARKS***

Claims 1 - 21 are in the case. Claims 3 through 16 and 18 through 21 are being amended.

The present preliminary amendment is submitted in order to eliminate multiple dependencies between claims.

Should be there any multiple dependent claims remaining, such remaining multiple dependent claims are to be deemed as treated as canceled by the applicant.

Entry of the above-recited corrections prior to calculation of the fee is respectfully requested.

Respectfully submitted,

Manrico Paulitschke et al.

By: 

Robert J. Ferb, their attorney  
13 Forest Drive, Warren, N.J. 07059  
Tel.: (908)526-1717; Reg.No. 29536  
Attorney's Docket No.: WEH205

\*%PAMEND(WEH205A1(June 19 2001(tm-yz/2419

1/PRTS

00/868887  
531 Rec'd PCT/... 20 JUN 2001

## Cardiovascular prostheses with a stable endothelial cell surface

### Description

5 The invention relates to cardiovascular prostheses with a stable, confluent endothelial cell surface which is produced by proliferation under a shear stress. Said cardiovascular prostheses are produced by means of a novel method for forming a stable confluent endothelial cell monolayer. Under the term "cardiovascular prostheses", vascular and heart  
10 valve prostheses are understood which are covered with endothelial cells on the blood contact side.

Methods for a blood contact side lining of cardiovascular prostheses with endothelial cells are known, even those, wherein a confluent endothelial cell monolayer is obtained by  
15 growth of the cells ensuing under static conditions, after an initial sub-confluent seeding or by means of a direct confluent settlement of the isolated cells (US-Patent 5,334,879). Thereby, the seeding may be carried out under a stepwise and/or permanent rotation, and also statically.

20 Implants from cell structures can also be produced by means of an absorbable carrier structure subsequent to enveloping the cells (DE 43 06 661), as a 3-dimensional, as well as a 2-dimensional implant, whereby carrier materials of different manufacture are possible (WO 94/17841). In the document EP 0 320 441, a method is described for conditioning plastic carriers covered with living cells – the adaptation to a shear stress is supposed to be  
25 obtained. Thereby, a periodically interrupted medium current is used – a permanent shear stress is not applied. In this case, it is the conditioning of the carrier covered confluent with cells and a habituation of the deposited cells to shear stress which is concerned, and not an adaptation of the cells as early as during their division and adhesion processes.

30 The application of shear forces is also the subject matter of the document WO 93/01843. According thereto, however, only shear forces of a very small amount and mainly of a radial orientation are applied. The seeding of the cells thereby ensues under static conditions, with a 4-fold rotation of the prosthesis every 20 minutes by about 90 degrees,

and only after this, a permanent shear stress of a very small amount is generated by rotation on a roller (10 revs./min).

The laid-open document WO 94/25584 reports on the formation of a closed cell monolayer which is generated as early as during the seeding. The initial adhesion takes place under static conditions. Subsequent thereto ensues the incubation of the confluent sown monolayer for over 24 hours. Here, the adaptation of the cells to physiological parameters of the shear stress does not ensue during the proliferation, either. US Patent 5,634,879 reports on a method providing sowing of the cells directly on the prosthesis after the isolation, without aiming at obtaining an adaptation of the cells to an increased defined shear stress. The cells are thereby deposited to the inner surface by means of a transversal filtration of the suspension through the prosthesis material. A closed circulation perfusion does not exist here. No proliferation under defined flow conditions ensues either.

The disadvantage of the described inventions consists in that either the proliferation behavior of the cells under static conditions entails a reduced adhesion of the cells on the prosthesis surface due to a modified gene expression, or no conditions are simulated *in vitro* which correspond to those of the *in vivo* situation.

The object of the present invention consists in developing cardiovascular prostheses by means of which the mentioned disadvantages can be countered.

This task was solved in that in cardiovascular prostheses with an endothelial cell surface, the formation of a confluent monolayer ensues subsequent to an initial sub-confluent population of the surface on the blood contact side. This ensues by the cells growing under a permanent influence of defined pulsatile shear forces increasing up to physiological values, by means of streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis in an inner perfusion circuit, and in that a moistening of the outer prosthesis wall ensues in an outer perfusion circuit or in a permeable medium reservoir.

The essence of the invention resides in a combination of known elements (method for forming a confluent monolayer on the surface of cardiovascular prostheses) and novel

elements (adaptation of the endothelial cells to a hemodynamic shear stress locally present in the blood vessel at the implantation location), which mutually influence and result in their entire action in an advantage of use and the desired success, which resides in that the hemodynamic shear stress directly influences the structure and function of the endothelial cells, and therewith causes an influence on the formation of a confluent endothelial cell monolayer as early as during their growth (cell division phase).

Surprisingly, it has been found that during the formation of the confluent endothelial cell monolayer by cell division, the cell population already becomes adapted to wall shear stress such as they can be observed *in vivo*, with the consequence of a stable adhesion of the cells to the prosthesis surface on the blood contact side, which is of decisive importance for the long-term structural and functional efficiency of the endothelial cell monolayer as an interface between prosthesis surface and the flowing blood. Therewith, the formation of a novel prosthesis surface comparable to *in vivo* linings of blood vessels is achieved, and as a result thereof, a significant reduction of the coagulation risk as compared to uncoated prostheses, or prostheses which are not confluent lined with endothelial cells.

Already known methods are characterized by a seeding of the prosthesis surface ensuing initially and under static conditions, which is only interrupted for short periods and discontinuously for exchanging the medium (EP 0 320 441). Further known are methods wherein the adjustment of the adherence of the cells on the prosthesis surface always takes place along with the formation of the immediate confluence (WO 93/01843). Thus, no proliferation of the endothelial cells under a permanent influence of defined pulsatile shear forces ensues (WO 94/25584).

The invention permits *inter alia* an adaptation of the cells to various values of wall shear stress under consideration of the shear forces arising later locally in the implant in dependence of the implant location, as early as before the implantation of the prosthesis in the blood circulation.

The increasing shear forces can be generated by means of a program-controlled pumping device (7). The mathematical value of the increasing shear forces can be selected variably and time-independently. According to an advantageous configuration, the mathematical value and the final value of the shear forces are allowed to be selected freely

and time-variably via a program control corresponding to the physiological conditions of the implant location, and therewith allow for the formation of arterial as well as venous vascular prostheses (1), according to the various wall shear stresses occurring *in vivo*, and also allow for the adaptation to pulsatile flow conditions.

5        According to a further advantageous configuration, the mathematical value of the occurring shear forces can be adjusted by varying the pumping capacity, as well as by varying the size of the cross-sections of the pumping tubes used or of any other connecting elements outside of the chamber, as well as by the geometrical form and configuration of the very chamber.

10        According to a further advantageous configuration, the outer perfusion circuit (5') can be operated in co-current or in counter-current to the inner perfusion circuit (5), but can also be operated statically. The two perfusion circuits (5, 5') can also work as a non-closed system; according to a further advantageous configuration, they lead from one medium reservoir (6) into another medium reservoir (6'), in which the medium which has  
15        already flowed through the prosthesis is collected. Thereby, the two circuits can also be joined within the chamber (2) after having flowed past the prosthesis surface.

      The inner and the outer perfusion circuit can have different reservoirs or one and the same medium reservoir (6, 6'). The prosthesis can be present in the very medium reservoir, and thereby, the inner and the outer perfusion circuit can be connected with one  
20        another.

      The formation of a confluent endothelial cell monolayer following the seeding of the prosthesis surface on the blood contact side, ensues by means of a perfusion circuit, illustrated in Figure 1 and Figure 2. This circuit is comprised of an inner perfusion circuit for streaming past the prosthesis surface on the blood contact side along the main axis of  
25        the prosthesis inside of a perfusion chamber, whereby the prosthesis is fixed and aligned in the inner space of the perfusion chamber by means of an adapter, and therewith constitutes itself a part of the inner perfusion circuit, and is further comprised of an outer perfusion circuit for outwardly streaming past the vascular prosthesis within the same perfusion chamber, which comprises, towards the outside, connections to a pumping device for both  
30        circuits, as well as to the medium reservoirs which can be exchanged under sterile conditions, and which also have the function of a pressure equation reservoir.

The outer perfusion circuit serves for moistening the outer prosthesis surface so as to prevent it from drying out. The prosthesis material is often of a high porosity, and can be impregnated prior to the seeding of cells, with fibrin or any other adhesion-promoting substances. An optional perfusion prevents possible gradients from forming in the medium composition, as well as of the pH value at and/or through the prosthesis wall. Thus, a gradient-dependent transversal diffusion through the prosthesis material is prevented from arising.

The invention hence relates to cardiovascular prostheses produced by a novel method characterized by the formation of a stable, confluent endothelial cell monolayer on the surface of the prostheses on the blood contact side. Thereby, the initial seeding of the prosthesis surface on the blood contact side, as well as the following growth of the endothelial cells to a confluent monolayer, ensues under the permanent influence of shear stress generated in two stages: initially, in the seeding phase for generating a sub-confluent endothelial cell monolayer by axial rotation of the culture chamber, and subsequently, by streaming the prosthesis surface along the main axis of the prosthesis. Therewith, conditions are created *in vitro* on the prosthesis surface on the blood contact side, which are comparable to those of the *in vivo* situation. As a result therefrom, a confluent endothelial layer having a high quality is formed.

These novel cardiovascular prostheses ensure markedly improved bonding of the cells on the surface of the prosthesis on the blood contact side and hereby enable the monolayer to be maintained even over long periods and under increased shear stress conditions. Hereby, for the first time, a significant reduction of the risk of coagulation is provided as compared to uncoated prostheses which are not confluent lined with endothelial cells, as well as compared to prostheses which have been confluent populated but exhibit an insufficient bonding of the cells on the prosthesis surface on the blood contact side. This method is suitable for covering heart valves as well as vascular prostheses such as they are used in cardiovascular surgery, hence also stents.

The inventive method consists in that, after an initial sub-confluent seeding of the prosthesis surface on the blood contact side, the formation of a confluent monolayer ensues by the cells growing under a permanent influence of defined pulsatile shear forces



increasing up to physiological values, by means of causing a streaming to occur about the prosthesis surface along the main axis of the prosthesis in an inner perfusion circuit, and by moistening the outer prosthesis wall in an outer perfusion circuit or in a permeable medium reservoir.

5

The invention will be explained in detail by means of examples, however, without being limited to these.

### Examples

10

#### Example 1:

A poly(tetrafluoroethylene) bypass prosthesis (Fig. 1: 1) having a diameter of 4 mm and a length of 15 cm is fixed to the inner space of the perfusion chamber (Fig. 1: 2), and hence connected to the inner perfusion circuit (Fig. 1: 5) by means of the adapters (Fig. 1: 3, 3') configured as olive, cones with a clamping or expanding device, respectively. The pulsatile flow (0 – 3,500 ml/h of endothelial cell culture medium) is generated by a peristaltic pump which can be freely and time-variably controlled manually or by a software program (Fig. 1: 7). Via tube connectors (Fig. 1: 4, 4'), which are decentrally mounted at the sides of the perfusion chamber, the outer perfusion circuit (Fig. 1: 5') which is perfused in co-current with the inner circulation, is established by means of silicone tubes. The two perfusion circuits (Fig. 1: 5, 5') each dispose of a reservoir (Fig.: 6, 6') containing endothelial cell culture medium and having simultaneously the function of a pressure equation reservoir. The peristaltic pump (Fig. 1: 7) is so controlled by a computer that the shear forces introduced by a pulsatile flow increase in the prosthesis over a period of 10 hours from 0.01 to 2.5 dyn/cm<sup>2</sup>. Thereafter, the flow conditions remain constant until the day of the implantation.

Subsequently, the chamber is opened in a sterile environment, and the prosthesis, confluent covered with cells, is ready to be implanted.

30

#### Example 2:

A Dacron® bypass prosthesis (Fig. 1: 1) having a diameter of 5 mm and a length of 10 cm is fixed to the inner space of the perfusion chamber (Fig. 1: 2), and hence connected to the inner perfusion circuit (Fig. 1: 5) by means of the adapters (Fig. 1: 3, 3'). The pulsatile flow (0 – 7,000 ml/h of endothelial cell culture medium) is generated by a peristaltic pump which can be freely and time-variably controlled manually or by a software program (Fig. 1: 7). The outer perfusion circuit is filled (Fig. 1: 5') with medium and statically operated. The two perfusion circuits (Fig. 1: 5, 5') dispose of a common reservoir containing endothelial cell culture medium and serving simultaneously as a pressure equation reservoir. Hereby, expandable blood bags made of the materials ethylene vinyl acetate M (EVAM) or polyvinyl chloride (PVC) are used.

The peristaltic pump (Fig. 1: 7) is so controlled by a computer that the shear forces introduced by a pulsatile flow increase in the prosthesis over a period of 24 hours from 0.01 to 5 dyn/cm<sup>2</sup>. Thereafter, the flow conditions remain constant until the day of the implantation.

Subsequently, the chamber is opened in a sterile environment, and the prosthesis, confluent covered with cells, is ready to be implanted.

### Example 3:

A poly(tetrafluoroethylene) vascular prosthesis (Fig. 1: 1) having a diameter of 10 mm and a length of 12 cm is fixed in the inner space of the medium reservoir which therewith represents the outer perfusion circuit, by means of an adapter. The pulsatile flow (0 – 7,000 ml/h of endothelial cell culture medium) is generated by a peristaltic pump which can be freely and time-variably controlled manually or by a software program (Fig. 1: 7), whereby the inner diameter of the pump tubes is variable.

The peristaltic pump (Fig. 1: 7) is so controlled by a computer that the shear forces introduced by a pulsatile flow increase in the prosthesis over a period of 24 hours from 0.01 to 5 dyn/cm<sup>2</sup>. Thereafter, the flow conditions remain constant until the day of the implantation.

Subsequently, the chamber is opened in a sterile environment, and the prosthesis, confluent covered with cells, is ready to be implanted.

Example 4:

A poly(tetrafluoroethylene) bypass prosthesis (Fig. 1: 1) having a diameter of 4 mm and a length of 4 cm is fixed to the inner space of the perfusion chamber (Fig. 1: 2), and hence connected to the inner perfusion circuit (Fig. 1: 5) by means of the adapters (Fig. 1: 3, 3') configured as olive, cones with a clamping or expanding device, respectively. The pulsatile flow (0 – 3,500 ml/h of endothelial cell culture medium) is generated by a peristaltic pump which can be freely and time-variably controlled manually or by a software program (Fig. 1: 7). Via tube connectors (Fig. 1: 4, 4'), which are decentrally mounted at the sides of the perfusion chamber, the outer perfusion circuit (Fig. 1: 5') which is perfused in counter-current with the inner circulation, is established by means of silicone tubes. Hereby, the perfusion of one or of both circulation/s ensues in a non-closed system. Thereby, medium flows from one medium reservoir serving as a storage into another medium reservoir serving as a collecting vessel.

The peristaltic pump (Fig. 1: 7) is so controlled by a computer that the shear forces introduced by a pulsatile flow increase in the prosthesis over a period of 10 hours from 0.01 to 2.5 dyn/cm<sup>2</sup>. Thereafter, the flow conditions remain constant until the day of the implantation.

Subsequently, the chamber is opened in a sterile environment, and the prosthesis, confluent covered with cells, is ready to be implanted.

Example 5:

A heart valve prosthesis (Fig. 1: 1) is fixed to the inner space of the perfusion chamber (Fig. 1: 2), and hence connected to the inner perfusion circuit (Fig. 1: 5) by means of an adapter (Fig. 1: 3). The pulsatile flow (0 – 7,000 ml/h of endothelial cell culture medium) is generated by a peristaltic pump which can be freely and time-variably controlled manually or by a software program (Fig. 1: 7). The outer perfusion circuit is perfused (Fig. 1: 5') in co-current. After streaming past the heart valve prosthesis, the two perfusion circuits unite inside of the chamber (2) until leaving same. The two perfusion circuits (Fig. 1: 5, 5') dispose of a common reservoir containing endothelial cell culture medium and serving simultaneously as a pressure equation reservoir. Hereby, expandable

blood bags made of the materials ethylene vinyl acetate M (EVAM) or polyvinyl chloride (PVC) are used.

The peristaltic pump (Fig. 1: 7) is so controlled by a computer that the shear forces introduced by a pulsatile flow increase in the prosthesis over a period of 24 hours from  
 5 0.01 to 5 dyn/cm<sup>2</sup>. Thereafter, the flow conditions remain constant until the day of the implantation.

Subsequently, the chamber (2) is opened in a sterile environment, and the prosthesis, confluent covered with cells, is ready to be implanted.

## 10 Figures

Figure 1 shows the schematic structure of a closed perfusion system. The chamber (2) constitutes the main element which is connected, via tube connectors (4, 4') to the inner circuit (5) and the outer circuit (5') with the pumping device (7) and the associated medium  
 15 reservoirs (6, 6'). The inner circuit is closed by the vascular prosthesis (1) fixed in the chamber by means of the adapters (3, 3'). The arrows shown symbolize the flow direction of the perfusing medium, whereby in the present illustration, a perfusion of the two circuits ensues in co-current.

Figure 2 shows the schematical structure of a perfusion system according to Figure 1, here,  
 20 however, the perfusion does not take place by means of two closed circuits, but from one medium reservoir (6) into another medium reservoir (6'), in which the medium is collected which has already streamed through the prosthesis.

Reference numerals

	1	cardiovascular prosthesis
	2	chamber
5	3, 3'	adapters
	4, 4'	tube connector
	5	inner circuit
	5'	outer circuit
	6, 6'	medium reservoir
10	7	pump

## Claims

1. Cardiovascular prostheses with an endothelial cell surface produced in that after an initial sub-confluent seeding of the surface on the blood contact side, the formation of a confluent monolayer ensues by the cells growing under a permanent influence of defined pulsatile shear forces increasing up to physiological values, by means of streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis in an inner perfusion circuit and by moistening the outer prosthesis wall in an outer perfusion circuit, or in a permeable medium reservoir.
2. Cardiovascular prostheses according to claim 1, characterized in that the increasing shear forces are generated by means of a program-controlled pumping device (7).
3. Cardiovascular prostheses according to claims 1 and 2, characterized in that the mathematical value of the increasing shear forces can be selected variably and time-independently.
4. Cardiovascular prostheses according to claims 1 through 3, characterized in that the mathematical value and the final value of the shear forces can be selected freely and time-variably by means of a program control according to the physiological conditions of the implantation location.
5. Cardiovascular prostheses according to claims 1 through 4, characterized in that the mathematical value of the occurring shear forces can be adjusted by varying the pumping capacity, as well as by varying the size of the cross-section of the pumping tubes used or of any other connecting elements outside of the chamber, as well as by the geometrical form and configuration of the very chamber.
6. Cardiovascular prostheses according to claims 1 through 5, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis

inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of adapters (3, 3'), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion circuit (5') for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connections to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.

7. Cardiovascular prostheses according to claims 1 through 6, produced by means of a perfusion circuit consisting of an inner perfusion circuit (5) for streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis inside of the chamber (2), said prosthesis (1) being fixed in the inner space thereof by means of an adapter (3), and hence constituting as such the inner perfusion circuit (5), and an outer perfusion circuit (5') uniting inside of the chamber (2) with the inner perfusion circuit (5) after having streamed the prosthesis (1) for outwardly streaming the prosthesis (1) within the same chamber (2) which comprises, towards the outside, connectors to a pumping device (7) for both circuits (5, 5'), as well as to the medium reservoirs (6, 6') which also have the function of pressure equation reservoir.

8. Cardiovascular prostheses according to claims 6 and 7, characterized in that the outer perfusion circuit (5') can be operated in co-current or in counter-current to the inner perfusion circuit (5), but also statically.

9. Cardiovascular prostheses according to claims 6 through 8, characterized in that the perfusion circuits lead from one medium reservoir (6) into another medium reservoir (6'), in which the medium is collected which has already streamed through the prosthesis.

10. Cardiovascular prostheses according to claims 6 through 8, characterized in that the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6').

11. Cardiovascular prostheses according to claims 6 through 8, characterized in that the prosthesis is present in the very medium reservoir, and that the inner and the outer perfusion circuits are thereby connected with each another.
- 5
12. Cardiovascular prostheses according to claims 6 through 11, characterized in that the medium reservoirs are comprised of expandable blood bags of the materials PVC or EVAM.
- 10
13. Cardiovascular prostheses according to claims 6 and 7, characterized in that the realization of the adapters (3, 3') for fixing the prosthesis (1) can be realized as an olive, cones with clamping means or as an expansion member.
- 15
14. Cardiovascular prostheses according to claims 6, 7 and 13, characterized in that the length of the prosthesis to be clamped can be varied by constructionally providing at least one closing part with the adapter (3 or 3') of chamber (2).
- 20
15. Cardiovascular prostheses according to claims 6 and 7, characterized in that the chamber (2) is manufactured from a transparent material.
- 25
16. Cardiovascular prostheses according to claims 1 through 15, characterized in that the prosthesis is used as a vascular prosthesis, a heart valve prosthesis or a stent.
- 30
17. Method for covering cardiovascular prostheses with endothelial cells according to claims 1 through 16, characterized in that after an initial sub-confluent seeding of the prosthesis surface on the blood contact side, the formation of a confluent monolayer ensues by the cells growing under permanent influence of defined pulsatile shear forces increasing up to physiological values by means of streaming the prosthesis surface on the blood contact side along the main axis of the prosthesis in an inner perfusion circuit, and a moistening of the outer prosthesis wall in an outer perfusion circuit or in a permeable medium reservoir.



18. The method according to claim 17, characterized in that
- a) the increasing shear forces are generated by means of a program-controlled pumping device (7),
  - 5 b) the mathematical value of the increasing shear forces can be selected variably and time-independently,
  - c) the mathematical value and the final value of the shear forces can be selected freely and time-variably by a program control according to the physiological conditions of the implantation location, and
  - 10 d) the mathematical value of the arising shear forces can be adjusted by varying the pumping capacity, as well as by varying the size of the cross-section of the pumping tubes used or of any other connecting elements outside of the chamber, as well as by the geometrical form and configuration of the very chamber.
- 15 19. The method according to claims 17 and 18, characterized in that in an inner perfusion circuit (5) for streaming through the inner prosthesis space along the main axis of the prosthesis inside of the chamber (2), the prosthesis (1) is fixed by means of adapters (3, 3'), and hence as such constitutes the inner perfusion circuit (5), and
- 20 that an outer perfusion circuit (5') exists for outwardly streaming the prosthesis (1) in the same chamber (2) which, towards the outside, comprises for the two circuits (5, 5') connectors to a pumping device (7) and the medium reservoirs (6, 6') which also have the function of pressure equation reservoirs.
- 25 20. The method according to claims 17 through 19, characterized in that
- a) the outer perfusion circuit (5') can be operated in co-current or counter-current to the inner perfusion circuit (5), but also statically,
  - b) the two perfusion circuits (5, 5') do not work as a closed system but lead from one medium reservoir (6) into another medium reservoir (6'), in which
  - 30 the medium is collected which has already streamed through the prosthesis,

- c) the inner and the outer perfusion circuits have different medium reservoirs or one and the same medium reservoir (6, 6'), and
- d) the two perfusion circuits (5, 5') unite inside the chamber (2) after having streamed the prosthesis (1), but leave the chamber (2) in separate perfusion circuits (5, 5').

5

21. The method according to claims 17 through 20, characterized in that the prosthesis is present in the very medium reservoir and that the inner and the outer perfusion circuits are thereby connected with each another.

10


11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## Abstract


The invention relates to cardiovascular prostheses with a stable, confluent endothelial cell surface which is produced by proliferation under a shear stress. Said cardiovascular  
5 prostheses are produced by means of a novel method for creating a stable confluent endothelial cell monolayer. The inventive cardiovascular prostheses ensure markedly improved bonding of the cells on the surface of the prosthesis and hereby enable the monolayer to be maintained even over long periods and in more demanding shear stress conditions. The invention hereby provides the first means of significantly reducing the risk  
10 of coagulation compared to uncoated prostheses which are not confluent lined with endothelial cells and prostheses which have been confluent populated but exhibit an insufficient bonding of the cells on the surface.

1 / 1

Figur 1



Figur 2



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Manrico Paulitschke et al.

Serial No: Art Unit:

Filing Date:

Title: CARDIOVASCULAR PROSTHESES WITH A STABLE  
ENDOTHELIAL CELL SURFACE

**DECLARATION AND POWER OF ATTORNEY FOR PATENT  
APPLICATION**

**Erklärung Für Patentanmeldungen Mit Vollmacht**

German Language Declaration Weh205

Als nachstehend benannter Erfinder erkläre ich hiermit an Eidesstatt:

As a below named inventor, I hereby declare that:

daß mein Wohnsitz, meine Postanschrift und meine Staats-angehörigkeit den im  
Nachstehenden nach meinem Namen aufgeführten Angaben entsprechen,

My residence, post office address and citizenship are as stated below next to  
my name,

daß ich, nach bestem Wissen der ursprüngliche, erste und alleinige Erfinder (falls  
nachstehend nur ein Name angegeben ist) oder ein ursprünglicher, erster und  
Miterfinder (falls nachstehend mehrere Namen aufgeführt sind) des Gegenstandes  
bin, für den dieser Antrag gestellt wird und für den ein Patent beantragt wird für die  
Erfindung mit dem Titel:

Kardiovaskuläre prothesen mit Endthelzell-Oberfläche

I believe I am the original, first and sole inventor (if only one name is listed  
below) or an original, first and joint inventor (if plural names are listed below)  
of the subject matter which is claimed and for which a patent is sought on the  
invention entitled:

## CARDIOVASCULAR PROSTHESES WITH A STABLE ENDOTHELIAL CELL SURFACE

deren Beschreibung (nur eines der nachfolgenden Kästchen ankreuzen)

the specification of which (check only one item below)

< > hier beigelegt ist.

is attached hereto.

< > am \_\_\_\_\_ als U.S.-Anmeldung, Seriennummer \_\_\_\_\_  
gereicht wurde und am \_\_\_\_\_ abgeändert wurde (falls tatsächlich  
abgeändert).

was filed as US Application Serial No. \_\_\_\_\_  
on \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

< X > am 17. Dezember 1999 als internationale PCT-Anmeldung, Nummer  
PCT/DE99/04102 eingereicht wurde und am \_\_\_\_\_ unter PCT-Artikel  
34/36 abgeändert wurde (falls tatsächlich abgeändert).

was filed as PCT international application, Number PCT/DE99/04102 on December  
17, 1999 and was amended under PCT Article 34/36 on \_\_\_\_\_ (if  
applicable)

Ich bestätige hiermit, daß ich den Inhalt der obigen Patentanmeldung einschließlich  
der Ansprüche durchgesehen und verstanden habe, die eventuell durch einen  
Zusatzantrag wie oben erwähnt abgeändert wurde.

I hereby state that I have reviewed and understand the contents of the above-  
identified specification, including the claims, as amended by any amendment referred  
to above.

Ich erkenne meine Pflicht zur Offenbarung jeglicher Informationen an, die zur  
Prüfung der Patentfähigkeit in Einklang mit Titel 37, Bundesgesetzbuch (Code of  
Federal Regulation), § 1.56 von Belang sind.

I acknowledge the duty to disclose information which is material to patentability as  
defined in Title 37, Code of Federal Regulations, § 1.56.

Ich beanspruche hiermit ausländische Prioritätsvorteile gemäß Abschnitt 35 der Zivilprozeßordnung der Vereinigten Staaten, Paragraph 119 jeglicher unten angegebenen Auslandsanmeldung(en) für ein Patent oder Erfindersurkunde oder jeglicher internationalen PCT-Anmeldung(en), welche mindestens ein Land ausser den Vereinigten Staaten benennt, und habe auch jegliche Auslandsanmeldung(en) für ein Patent oder Erfindersurkunde oder jegliche internationale PCT-Anmeldung(en), welche mindestens ein Land ausser den Vereinigten Staaten benennt, nachstehend gekennzeichnet, welche von mir für den gleichen Gegenstand eingereicht wurde und ein Anmeldedatum haben, das vor dem Anmeldedatum der Anmeldung liegt, für die Priorität beansprucht wird.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN /PCT APPLICATION(S) AND ANY PRIORITY CLAIMS  
UNDER**

**35 USC 119:**

**FRÜHERE AUSLÄNDISCHE/PCT ANMELDUNG(EN) UND JEDLICHE  
PRIORITÄT UNTER**

**35 USC 119:**

Country	Application No.	Date of Filing	Priority Claimed
(if PCT, indi- cate PCT)		(day, month, year)	under 35 USC 119

Land (falls PCT, PCT angeben)	Anmeldungs- nummer	Anmeldedatum (Tag, Monat, Jahr)	Priorität unter 35 USC 119 beansprucht
-------------------------------------	-----------------------	------------------------------------	--

Germany	198 60 286.3	21 December 1998	<X>Yes <>No Ja Nein
---------	--------------	------------------	------------------------

Ich beanspruche hiermit gemäß Absatz 35 der Zivilprozeßordnung der Vereinigten Staaten, Paragraph 120, den Vorzug jeglicher unten aufgeführten U.S.-Anmeldung(en) oder die USA benennende internationale(n) PCT-Anmeldung(en) und falls der Gegenstand aus jedem Anspruch dieser Anmeldung nicht in

dieser/diesen früheren Patentanmeldung(en) laut dem ersten Paragraphen des Absatzes 35 der Zivilprozeßordnung der Vereinigten Staaten, Paragraph 112 offenbart ist, erkenne ich gemäß Absatz 37, Bundesgesetzbuch, Paragraph 1.56(a) meine Pflicht zur Offenbarung von Informationen an, die zwischen dem Anmeldedatum der früheren Anmeldung(en) und dem nationalen oder internationalen PCT Anmeldedatum dieser Anmeldung bekannt geworden sind.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS  
DESIGNATING  
THE U.S. FOR BENEFIT UNDER 35 USC 120:  
FRÜHERE AMERIKANISCHE ANMELDUNGEN ODER DIE USA  
BENENNENDE  
INTERNATIONALE PCT-ANMELDUNGEN FÜR VORRECHT UNTER 35 USC  
120

U.S. APPLICATIONS		STATUS (Check one)	
U.S. Application No.	U.S Filing Date	Patented	Pending Abandoned
AMERIKANISCHE ANMELDUNGEN		STAND (ein Kästchen ankreuzen)	
Seriennummer	Anmeldedatum	Patentiert	Anhängig Aufgegeben

<> <> <>

PCT APPLICATIONS DESIGNATING THE U.S.  
PCT Application PCT Filing Date U.S.Ser.Nos.  
Number assigned (if any)

DIE USA BENENNENDE PCT-ANMELDUNGEN  
PCT-Anmelde- PCT-Anmeldedatum Zugeteilte Serien-  
nummer nummern (falls zutreffend)

<> <> <>

VERTRETUNGSVOLLMACHT: Als benannter Erfinder beauftrage ich hiermit den nachstehend benannten Patentanwalt (oder die nachstehend benannten Patentanwälte)



und/oder Patent-Agenten mit der Verfolgung der vorliegenden Patentanmeldung sowie mit der Abwicklung aller damit verbundenen Geschäfte vor dem Patent- und Warenzeichenamt: (Name und Registrationsnummer anführen)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Horst M. Kasper (Reg. No. 28,559)

Richard T. Laughlin (Reg. No. 17,264)

Telefongespräche bitte richten an: (Name und Telefonnummer)

Direct Telephone Calls to: (Name and telephone number)

Horst M. Kasper (908) 757-2839

Postanschrift:

Send Correspondence to:

13 Forest Drive Warren, N.J. 07059

Ich erkläre hiermit, daß alle von mir in der vorliegenden Erklärung gemachten Angaben nach meinem besten Wissen und Gewissen der vollen Wahrheit entsprechen, und daß ich diese eidesstattliche Erklärung in Kenntnis dessen abgebe, daß wissentlich und vorsätzlich falsche Angaben gemäß Paragraph 1001, Absatz 18 der Zivilprozeßordnung der Vereinigten Staaten von Amerika mit Geldstrafe belegt und/oder Gefängnis bestraft werden können, und daß derartig wissentlich und vorsätzlich falsche Angaben die Gültigkeit der vorliegenden Patentanmeldung oder eines darauf erteilten Patenten gefährden können.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Voller Name des einzigen oder ursprünglichen Erfinders:

Full name of sole or first inventor:

Manrico Paulitschke

Unterschrift des Erfinders

Inventor's signature

Datum

Date

30.07.01

Wohnsitz

Residence

D-13086 Berlin

Germany

Staatsangehörigkeit

Citizenship

Germany

Postanschrift

Post Office Address

Pistoriusstrasse 103

D-13086 Berlin

Germany

Full name of second inventor:

Axel Rademacher

Unterschrift des Erfinders

Inventor's signature

Datum

Date

30.07.01

Wohnsitz

Residence

D-10319 Berlin


Germany

Staatsangehörigkeit

Citizenship


Germany

Postanschrift  
Post Office Address  
Mellenseestrasse 25  
D-10319 Berlin  
Germany

  
Full name of third inventor:  
Michael Sittinger

Unterschrift des Erfinders  
Inventor's signature

Datum  
Date



30.7.01

Wohnsitz  
Residence  
D-15831 Grossziethen  
Germany  
Staatsangehörigkeit  
Citizenship  
Germany

DEX

Postanschrift  
Post Office Address  
Karl-Marx-Strasse 147D  
D-15831 Grossziethen  
Germany

PTO 1391 (10-83)  
\*%pt0:germde(WEH205DE(June 15, 2001(th/mw